Cancer remains one of the most formidable health challenges worldwide, affecting millions every year.

According to a study by Cancer Research UK, it’s estimated that there were 18.1 million new cancer diagnoses globally in 2020. This alarming figure underscores the rising trend in cancer diagnoses, the study states, “Worldwide there will be 28 million new cases of cancer each year by 2040.”

It’s not just about the overwhelming statistics but its profound impact on patients and their families. The treatment landscape, although progressing, still yearns for innovative breakthroughs.


NANOBIOTIX, a biotechnology firm aiming to provide new treatment solutions for cancer patients, has recently welcomed Dr. Louis Kayitalire as their chief medical officer. Dr. Kayitalire boasts a prolific background in the biopharmaceutical sector, primarily focusing on oncology. He has been an integral part of the development and commercialization of various oncology therapeutics.

Laurent Levy, co-founder and chairman of NANOBIOTIX, praised Dr. Kayitalire’s innovative clinical acumen, asserting that his experience would be paramount in forwarding the company’s ventures, especially regarding NBTXR3.

Dr. Kayitalire previously held significant roles at major companies like F-star Biotechnology, Bristol-Myers Squibb, Celgene, and Eli Lilly. He expressed his excitement about the potential of NBTXR3 in changing the landscape of cancer treatment.

NBTXR3 Overview

NBTXR3, a unique oncology product, comprises hafnium oxide nanoparticles. Administered via a single intratumoral injection, it is then activated using radiotherapy. The primary goal is to cause significant tumor cell death in the injected area upon activation, which should then stimulate an adaptive immune response against the cancer.

NANOBIOTIX believes that due to its mode of action, NBTXR3 could be adapted for any solid tumor treatable with radiotherapy and combined with any therapeutic combination, especially immune checkpoint inhibitors.

Current evaluations for NBTXR3 involve its application in various solid tumors either as a standalone or in combination with anti-PD-1 immune checkpoint inhibitors.

Furthermore, NANOBIOTIX has embarked on collaborations to simultaneously develop the product while focusing on its primary developmental pathways. Partnerships include those with The University of Texas MD Anderson Cancer Center, LianBio, and recently with Janssen Pharmaceutica NV.


Founded in 2003 and based in Paris, France, NANOBIOTIX is an advanced clinical biotechnology company. They are determined to redefine treatment outcomes for numerous patients by introducing groundbreaking physics-based therapeutic strategies.

The company holds over 20 umbrella patents linked to three distinct nanotechnology platforms. These platforms cater to oncology, bioavailability and biodistribution, and central nervous system disorders. Their principal focus is the development of NBTXR3, which has already received a CE marking in Europe for soft tissue sarcoma treatment under the brand name Hensify®.

While NANOBIOTIX remains a pivotal player in the field, other startups also contribute significantly to advancements in cancer treatment.

Among the many startups in this domain, Nanogenics stands out. They are a leading therapeutic provider that harnesses nanoscale technology and utilises siRNA to treat cancer and fibrotic diseases.

By leveraging their proprietary gene delivery technology, LipTide, they are adept at precisely delivering therapeutic siRNAs. Their premier drug, ECP-102, enhances the efficacy of chemotherapy by increasing the vulnerability of cancer cells to cell death.


The evolving landscape of cancer treatment is witnessing groundbreaking advancements spearheaded by entities like NANOBIOTIX. With the introduction of pioneering therapies, the future holds promise for more effective and diverse solutions in battling this global health crisis. Similarly, the contributions of startups such as Nanogenics emphasise a collective drive in the biotech community to push boundaries, offering hope and a brighter prognosis for patients worldwide.